Venkat, Rathnam K.
Hayashi, Keigo
Juge, Pierre-Antoine
McDermott, Gregory
Paudel, Misti
Wang, Xiaosong
Vanni, Kathleen M. M.
Kowalski, Emily N.
Qian, Grace
Bade, Katarina J.
Saavedra, Alene A.
Mueller, Kevin T.
Chang, Sung Hae
Dellaripa, Paul F.
Weinblatt, Michael E.
Shadick, Nancy A.
Doyle, Tracy J.
Dieude, Philippe
Sparks, Jeffrey A. https://orcid.org/0000-0002-5556-4618
Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01 AR080659, R01 AR077607, P30 AR070253, P30 AR072577)
Article History
Received: 24 April 2024
Revised: 2 June 2024
Accepted: 6 June 2024
First Online: 19 June 2024
Declarations
:
: Dr. Juge has performed consultancy for Galapagos and has received payment/honoraria from Boehringer Ingelheim and Novartis, all unrelated to this study. Dr. Weinblatt has performed consultancy for Abbvie, Amgen, Aclaris, Aqtual, Bristol Myers Squibb, Glaxo Smith Kline, Johnson and Johnson, Eli Lilly, Novartis, Prometheus, Pfizer, Rani, Revolo, Sanofi, Scipher, Sci Rhom, Set Point, and Biohaven, and holds stock in Canfite, Inmedix, and Scipher, all unrelated to this study. Dr. Doyle has been part of a clinical trial funded by Genentech unrelated to this study. Dr. Dieude has performed consultancy for Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Abbvie, Pfizer, Novartis, and Galapagos, and has participated on a data safety monitoring/advisory board for Bristol Myers Squibb, all unrelated to this study. Dr. Sparks has performed consultancy for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Inova Diagnostics, Janssen, Optum, Pfizer, ReCor, Sobi, and UCB unrelated to this study. The funders had no role in the decision to publish or preparation of this manuscript. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic health care centers, or the National Institutes of Health.